• Active, not recruiting

NCT03798678: Phase 1 - CB-839 HCl + Carfilzomib and Dex - Refractory MM

Updated: May 26

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Kd

CB-839 HCl + Carfilzomib and Dex

This phase I trial studies the best dose of CB-839 HCl when given together with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back or does not respond to previous treatment. CB-839 HCl and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.


Giving CB-839 HCl, carfilzomib, and dexamethasone may work better in treating patients with multiple myeloma.


Sponsor

National Cancer Institute (NCI)

 

ClinicalTrials.gov Identifier: NCT03798678


Official Title: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma


First Posted : January 10, 2019


Click here for details on ClinicalTrials.gov

 

Glutaminase Inhibitor CB-839 Hydrochloride - National Cancer Institute


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

 

Drug: Carfilzomib

Drug: Dexamethasone

Drug: Telaglenastat Hydrochloride

 

- Connecticut: Yale University New Haven

- Florida: Moffitt Cancer Center Tampa

- Minnesota: Mayo Clinic Rochester Minnesota

- New Jersey: Rutgers Cancer Institute of New Jersey New Brunswick

 

Locations

United States, Connecticut

United States, Florida

United States, Minnesota

United States, New Jersey

United States, Ohio



Posts Archive